Guerbet announces group purchasing agreement with Premier to distribute novel microcatheters

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Aktueller Standort:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Penumbra introduces latest stroke thrombectomy aspiration technology at SNIS 2019

AHRA and Canon Medical Systems support medical imaging innovation with the 12th annual putting patients first program

European Society of Cardiology hosting digital summit in Tallinn

Abbott receives U.S. approval of next-generation MitraClip, bringing new enhancements to Abbott's leading MitraClip platform

Telehealth Technology to reduce hospital readmissions and improve outcomes for cardiac disease patients

FDA approves Bayer's Gadavist (gadobutrol) injection as first contrast agent for use in cardiac MR in adult CAD patients

New technology improves atrial fibrillation detection after stroke

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Team approach to cardiac care increases chance of surviving heart attack complications

Guerbet announces group purchasing agreement with Premier to distribute novel microcatheters

Press releases may be edited for formatting or style
PRINCETON, N.J., June 18, 2019 /PRNewswire/ -- Guerbet LLC USA, the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging today announced a group purchasing agreement with Premier Inc., a leading healthcare improvement company for Guerbet's SeQure and DraKon, two novel microcatheters intended for the infusion of therapeutic agents, contrast media and embolics into peripheral vessels.

This agreement allows Premier members, at their discretion, to access both microcatheters, which offer optimal intra-arterial navigation to interventionalists and provide novel solutions to further enhance and secure embolization procedures.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



The SeQure device uses flow dynamics to create a fluid barrier designed to deliver treatment to a target vessel to reduce the risk of non-target embolization. The device features side slits specifically designed to allow the outflow of contrast media to create a fluid barrier around the microcatheter to reduce microspheres reflux and to aid in delivery to the target vessel. The DraKon peripheral device is a standard end hole microcatheter with optimized pushability, flexibility and torqueability.

"We are thrilled to work with Premier Inc. to provide their members with two of the leading microcatheter options in the USA," said Massimo Carrara, Guerbet Vice President for North America. "This agreement represents Guerbet's commitment to offering the best in interventional imaging in a rapidly evolving industry."


ABOUT GUERBET
Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018.


SOURCE Guerbet LLC USA

Cardiology Homepage


You Must Be Logged In To Post A Comment